Development of TGF-beta signalling inhibitors for cancer therapy
- PMID: 15573100
- DOI: 10.1038/nrd1580
Development of TGF-beta signalling inhibitors for cancer therapy
Abstract
The transforming growth factor-beta (TGF-beta) superfamily of ligands has a pivotal role in the regulation of a wide variety of physiological processes from development to pathogenesis. Since the discovery of the prototypic member, TGF-beta, almost 20 years ago, there have been tremendous advances in our understanding of the complex biology of this superfamily. Deregulation of TGF-beta has been implicated in the pathogenesis of a variety of diseases, including cancer and fibrosis. Here we present the rationale for evaluating TGF-beta signalling inhibitors as cancer therapeutics, the structures of small-molecule inhibitors that are in development and the targeted drug discovery model that is being applied to their development.
Similar articles
-
Targeting TGFbeta-mediated processes in cancer.Curr Opin Drug Discov Devel. 2009 Mar;12(2):253-63. Curr Opin Drug Discov Devel. 2009. PMID: 19333871 Review.
-
Targeting the transforming growth factor-beta signalling pathway in metastatic cancer.Eur J Cancer. 2010 May;46(7):1232-40. doi: 10.1016/j.ejca.2010.02.040. Epub 2010 Mar 20. Eur J Cancer. 2010. PMID: 20307969 Review.
-
Large- and small-molecule inhibitors of transforming growth factor-beta signaling.Curr Opin Investig Drugs. 2006 Jun;7(6):513-21. Curr Opin Investig Drugs. 2006. PMID: 16784021 Review.
-
TGF beta signalling and its role in tumour pathogenesis.Acta Biochim Pol. 2005;52(2):329-37. Epub 2005 Jun 25. Acta Biochim Pol. 2005. PMID: 15990918 Review.
-
Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models.Clin Exp Pharmacol Physiol. 2008 Mar;35(3):335-41. doi: 10.1111/j.1440-1681.2007.04876.x. Clin Exp Pharmacol Physiol. 2008. PMID: 18290874 Review.
Cited by
-
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.Cancers (Basel). 2022 Sep 12;14(18):4421. doi: 10.3390/cancers14184421. Cancers (Basel). 2022. PMID: 36139583 Free PMC article. Review.
-
Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.Breast Cancer Manag. 2014;3(1):73-85. doi: 10.2217/bmt.13.74. Breast Cancer Manag. 2014. PMID: 25904986 Free PMC article.
-
14-3-3ζ as a prognostic marker and therapeutic target for cancer.Expert Opin Ther Targets. 2010 Dec;14(12):1343-54. doi: 10.1517/14728222.2010.531011. Expert Opin Ther Targets. 2010. PMID: 21058923 Free PMC article. Review.
-
Transforming growth factor beta1-mediated activation of the smooth muscle alpha-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-alpha via mitogen-activated protein kinase kinase 1-dependent induction of the Egr-1 transcriptional repressor.Mol Biol Cell. 2009 Apr;20(8):2174-85. doi: 10.1091/mbc.e08-10-0994. Epub 2009 Mar 4. Mol Biol Cell. 2009. PMID: 19261809 Free PMC article.
-
Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis.Cell Oncol (Dordr). 2018 Apr;41(2):123-140. doi: 10.1007/s13402-018-0376-6. Epub 2018 Mar 22. Cell Oncol (Dordr). 2018. PMID: 29568985 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
